- Canadian Biotechnology Company advances pharmaceutical programs while
executing on non-pharmaceutical opportunities -
TSX symbol: SBS
CALGARY, March 17 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced its operational and financial results for the twelve-month period ended December 31, 2007.
"We made progress on multiple product candidates during 2007 that was
essential to setting the stage for significant value creating milestones in
2008. We believe that each of our candidates individually represent an
exciting and material opportunity to the growth of our company. The basis
for this growth is the flexibility of our proprietary oilbody-oleosin
technology which allows us to target multiple markets that require high
volume, cost-effective pharmaceutical and non-pharmaceutical products,"
said Andrew Baum, President and CEO of SemBioSys Genetics Inc.
"Establishing Botaneco as a separate operating company with genuine value
creating potential and achieving commercially viable levels of Apo AI
accumulation were some of the key highlights of the year for us.
Additionally, we have made significant progress on the insulin program
including the necessary preclinical work to submit an IND in order to begin
the Phase I/II clinical trial in the second half of 2008. While we have
adjusted the expected start date of the insulin clinical trial, we believe
the insulin program represents just one of the important upcoming
milestones for SemBioSys in 2008. We also expect in vivo functional and
efficacy results from Apo AI(Milano), which has the potential to attract
partnership opportunities as well as further growth and business
development opportunities from Botaneco. Our recent achievements have also
begun to attract interest from new potential partners that believe the
|SOURCE SemBioSys Genetics Inc.|
Copyright©2008 PR Newswire.
All rights reserved